论文部分内容阅读
为适应我国当前结核病防治工作的需要,2017年11月9日国家卫生和计划生育委员会发布了《WS 196-2017结核病分类》卫生行业标准.新的分类标准以结核病的病原学、流行病学特征、临床表现、实验室检测及鉴别诊断等为主要依据进行修订.修订内容以活动性结核病为主,为符合结核病发展变化客观规律及结核病迁延反复的特点,在肺结核的分类中,将气管、支气管结核和结核性胸膜炎纳入到肺结核分类中,并在痰菌检查结果中增加了分子生物学检查,统称为病原学检查结果.同时,将抗结核药物敏感性试验结果纳入到活动性结核病分类中;本标准同时涵盖了结核分枝杆菌潜伏感染和非活动性结核病,明确了这两类人群的判定标准,将更有利于结核病的重点防控.增加了耐药状况的分类,有利于了解耐药结核病状况及科学、客观地评价耐药结核病的流行现状.新的《WS 196-2017结核病分类》标准将为2035年实现我国终止结核病防控目标提供有力的技术支撑.“,”In order to meet the needs of the current tuberculosis prevention and control work in China,the National Health and Family Planning Commission (NHFPC) released the health industry standard for the Classification of tuberculosis (WS 196-2017) on November 9,2017.The new classification standards are based on the etiology,epidemiological characteristics,clinical manifestations,laboratory tests and differential diagnosis of tuberculosis.Amendments mainly focus on active TB,and it is in line with the characteristics of the change and development of tuberculosis.The trachea and bronchial tuberculosis and tuberculous pleurisy are incorporated into pulmonary tuberculosis.And the molecular and bacteriological examination result are defined as pathogenic examination.At the same time,the results of drug susceptibility test are included in the active tuberculosis classification.This standard also cover Mycobacterium tuberculosis latent infection and inactive pulmonary tuberculosis.The clear definition of the two groups are more conducive to the key prevention and control of tuberculosis.Increasing the drug resistance classification is beneficial to understand the status of drug-resistant tuberculosis and to evaluate the epidemic status of drug resistant tuberculosis scientifically and objectively.The Classification of tuberculosis (WS 196-2017) will provide a strong technical support for the realization of the goal of ending tuberculosis prevention and control in China in 2035.